Abstract:
OBJECTIVE: To study the capability of bioactive compounds to ameliorate the
neuronal destruction in animal model of Parkinson disease.
MATERIALS AND METHODS: Rotenone was used to produce the
Parkinsonism in mammalian model of rats and the bioactive compounds, chrysin,
polydatin and CGA were used to ameliorate the neuronal destruction and the
resulting effets of Parkinson in this study. A total of hundred male Sprague
Dawley albino rats of weight 200 to 250 gm were divided randomly into five
groups with twenty animals in each: control, rotenone+chrysin,
rotenone+polydatin and rotenone+chlorogenic acid (CGA) group. Rotenone was
dissolved in DMSO and migloyl 812 N at ratio of 2:98 respectively and was
administered intraperitoneally at a dose of 3 mg/kg, daily for four week to
produce the rat model of Parkinson disease. Mortality and weight changes were
assessed, various behavioral tests were performed throughout the experiment to
assess the neuro behavioral changes. At the end of experiment, animals were
sacrificed, brains were fixed by perfusion method and light microscopic sections
were prepared using H & E and cresyl violet method. Immunohistochemical
sections were also prepared using anti tyrosine hydroxylase antibody, anti α
synuclein antibody, anti ubiquitin antibody, to localize the damaged neurons and
amelioration done by bioactive compounds. Anti GFAP antibody was used to
localize the Astrocytes immunohistochemically. Dopaminergic neurons, α
synuclein and ubiquitin aggregations and astrocytes were analysed for anychanges in their morphology and count in substantia nigra and striatum in
Parkinsonism and the ameliorating effects of the bioactive compounds used in
this study on them.
RESULTS: Rotenone-induced Parkinsonism in animals showed a significant
loss of body weight and increase in mortality. Parkinson animals showed
deteriorating motor behaviour over the period of experiment. Parkinson animals
showed a decrease in dopaminergic neurons in nigrostriatal region. TH
immunohistochemistry (IHC) showed decreased immunoreactivity and number of
TH positive dopaminergic neurons. Ubiquitin and α-synuclein IHC showed
accumulation of α-synuclein & ubiquitin within the neuronal cytoplasm.
Astrogliosis with increase in number and amoeboid morphology was also seen.
Bioactive compounds not only significantly restored the rotenone-induced weight
loss but also the behavioural changes. These compounds also showed protective
effects in terms of less degeneration of nigrostriatal dopaminergic neurons and
diminished immunoreactivity to anti ubiquitin and anti α-synuclein antibodies.
These compounds also decreased the activation and number of astrocytes.
CONCLUSION: This study concludes that bioactive compounds confer
protection in rat model of Parkinson disease. They ameliorated the degeneration
of the dopaminergic neurons, accumulation of α-synuclein and ubiquitin in the
cytoplasm of neurons and activation & morphological alteration of astrocytes.